Clinical Trials Logo

Clinical Trial Summary

This is a single-arm, multicenter phase II clinical study. The aim is to evaluate the safety, tolerability, and anti-tumor activities of AK104(a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced gastric adenocarcinoma and colorectal cancer during the perioperative period.Eligible patients will receive AK104 for three cycles before surgery and at most 6 months after surgery. The primary endpoint is the pathological complete response rate.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04556253
Study type Interventional
Source Peking University
Contact Jiafu Ji, Professor
Phone 86-010-88196598
Status Not yet recruiting
Phase Phase 2
Start date October 2020
Completion date October 2023